ADVFN US – Market Content Editor
-
Founder Group shares jump 20% after securing $4.1M solar project contract
Shares of Founder Group (NASDAQ:FGL) climbed 20% on Monday after the company announced it had been awarded an Engineering, Procurement, Construction, and Commissioning (EPCC) contract valued at approximately RM16 million ($4.14 million) for a 25.40MW solar power project in Malaysia. The project forms part of Malaysia’s Corporate Green Power Programme (CGPP), a government initiative designed…
-
La Rosa Holdings signs LOI to acquire AI infrastructure firm Consensus Core Technologies
La Rosa Holdings Corp. (NASDAQ:LRHC), a real estate and PropTech company, said it has signed a non-binding letter of intent to acquire 100% of the outstanding equity interests of Consensus Core Technologies and certain related affiliates and subsidiaries. Consensus provides infrastructure solutions supporting artificial intelligence and high-performance computing. The proposed transaction would give La Rosa…
-
MDJM highlights growing policy backing for animation and creative sectors in the UK and Europe
MDJM LTD (NASDAQ:UOKA) said the animation and broader creative industries across the UK and Europe are benefiting from increasing policy support and economic importance, as governments place greater emphasis on cultural production as a driver of growth and innovation. The company noted that the UK’s creative industries are widely regarded as one of the country’s…
-
Nuvve Japan signs $3.35M deal for 2MW battery storage project in Gifu
NUVVE JAPAN K.K., the Japanese subsidiary of Nuvve Holding Corp. (NASDAQ:NVVE), has signed a definitive agreement to sell a front-of-the-meter battery energy storage system (BESS) for a project in Mino City, Gifu Prefecture, marking the company’s first completed sales agreement for a large-scale storage installation in the region. The project will feature a power output…
-
Regeneron reports 19% weight loss in China Phase 3 trial of olatorepatide
Regeneron Pharmaceuticals (NASDAQ:REGN) said Monday that partner Hansoh Pharmaceutical Group Company Limited reported positive results from a Phase 3 clinical trial evaluating olatorepatide in Chinese patients with obesity or who are overweight. The announcement comes as the $78 billion biotechnology company trades near its 52-week high, with shares up 59% from their lowest level over…
-
Strategy introduces new data management tools at 2026 Gartner Summit
Strategy (NASDAQ:MSTR) unveiled two new solutions—Mosaic Sentinel and Cloud Cost Arbitrage—during the Gartner Data & Analytics Summit 2026, aiming to strengthen transparency, oversight, and governance in modern data environments. As businesses increasingly adopt AI-driven agents to handle data processing and analytics tasks, the company said the new tools are designed to give organizations greater visibility…
-
Autozi Internet shares surge 108% following $110M investment proposal
Autozi Internet Technology (NASDAQ:AZI) shares soared on Monday after the company announced a two-part financing update that quickly drew investor interest. The firm said its controlling shareholder had already completed an early capital injection of $7 million, fulfilling a previously announced commitment ahead of schedule. According to the company, the funds have been fully received…
-
Amazon Pharmacy launches Zepbound KwikPen with $299 monthly starting price
Amazon Pharmacy (NASDAQ:AMZN) said it has begun offering Eli Lilly’s Zepbound KwikPen, a multi-dose injectable medication for weight management, with cash-pay pricing starting at $299 per month for the 2.5 mg introductory dose, according to a company press release. The offering further expands Amazon’s growing presence in healthcare as the $2.29 trillion company continues broadening…
-
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) surged 40% on Monday after the company reported positive topline data from its Phase 3 X-TOLE2 trial evaluating azetukalner for focal onset seizures. The study achieved its primary endpoint in both tested dose groups. Patients receiving the 25 mg dose experienced a median reduction of 53.2% in monthly focal…
-
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported a fourth-quarter loss of $1.43 per share on Monday, while revenue totaled $280 thousand for the quarter ended December 31, 2025. Shares of the biotechnology company surged 25.05% in pre-market trading following the announcement. The company revealed it had reached an early GO decision in its Phase 3 CAPTIVATE trial…